Comparison · not a ranking
ARA-290 compared with Cartalax
ARA-290 and Cartalax are separate catalogue items. They are not interchangeable.A CoA for every lot; each vial carries a printed lot number that matches it. Request yours and we email it within 2 hours. Research use only. Not a medicine.
Last verified 9 Nov 2026. UK prices checked daily.
ARA-290 and Cartalax are not the same material. ARA-290 is a 11-residue peptide, while Cartalax is a 3-residue peptide. ARA-290: C51H84N16O21, 1257.3 g/mol, CAS 1208243-50-8. Cartalax: C12H19N3O8, 333.29 g/mol, CAS 85806-95-7. By sequence, ARA-290 is pGlu-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser and Cartalax is Ala-Glu-Asp. In short, their molecular weights differ by about 924.0 g/mol; their sequences differ in length (11 versus 3 residues). Each has its own reference record, which lists the source for every figure above. Sable Peptides, a UK supplier operating since 2019, lists both as lyophilised research material; every vial carries a lot number and a certificate of analysis exists for every lot — request yours at /coa-request and we email it within 2 hours. This intro compares identity only and ranks neither compound. Research use only. Not a medicine. Not for human or veterinary use.
Sources: pubchem.ncbi.nlm.nih.gov · pubchem.ncbi.nlm.nih.gov
ARA-290 and Cartalax are two records in the Sable Peptides catalogue at https://www.sablepeptides.co.uk/versus/ara-290/cartalax. These prices are both Sable catalogue prices. They are not a comparison with another shop. This page does not rank either compound. Each page shows the catalogue price. A market comparison appears only when an exact, current, approved listing for that size is on record. Only a row with the same amount is a like-for-like price.
Research use only. Not a medicine. Not for human or veterinary use. Disclaimer
These two compounds have no identical amount, so no like-for-like price row is shown.
Reference facts
| Fact | ARA-290 | Cartalax |
|---|---|---|
| Molecular weight | 1257.3 g/mol | 333.29 g/mol |
| Molecular formula | C51H84N16O21 | C12H19N3O8 |
| CAS number | 1208243-50-8 | 85806-95-7 |
| Compound class | peptide | peptide |
Sources: pubchem.ncbi.nlm.nih.gov, pubchem.ncbi.nlm.nih.gov Verified 2026-11-09
- Category
- ARA-290Repair
- CartalaxShort sequences
- Research use only
- ARA-290Yes
- CartalaxYes
- Vials
- ARA-2902
- Cartalax2
- Record
- ARA-290ara-290
- Cartalaxcartalax
Questions this page answers
- How does ARA-290 compare with Cartalax?
- Same vial amounts are shown side by side with each catalogue price. Different amounts are not treated as the same price. No effect is compared, and another seller is not compared.
- Which is better?
- This page does not say. It does not rank safety, strength, or effect.
- What is the lowest catalogue price per mg for ARA-290 and Cartalax?
- ARA-290: £2.19/mg on the 16 mg vial (£35.00). Cartalax: £1.70/mg on the 10 mg vial (£16.99). Different compounds; this is a catalogue price fact, not a ranking.
- How many vial sizes are listed for each?
- ARA-290: 5 mg, 16 mg. Cartalax: 10 mg, 20 mg.
Both compounds
Related research
In-depth comparison
Sable research note. Updated 2026-10-10. Research use only.
Short answer
ARA-290 (cibinetide) and Cartalax are different compounds. ARA-290 (cibinetide) is an erythropoietin-derived linear peptide; Cartalax is a short regulatory tripeptide (Khavinson series). By PubChem's computed values, ARA-290 (cibinetide) (1257.3 g/mol) is about 3.8 times the mass of Cartalax (333.29 g/mol). Sable lists both as freeze-dried research material. Research use only: neither is sold as a medicine, and neither is for use in people or animals.
At a glance
| ARA-290 (cibinetide) | Cartalax | |
|---|---|---|
| Class | erythropoietin-derived linear peptide | short regulatory tripeptide (Khavinson series) |
| Formula (PubChem) | C51H84N16O21 | C12H19N3O8 |
| Molecular weight (PubChem, g/mol) | 1257.3 | 333.29 |
| PubChem CID | 91810664 | 87815447 |
| Sable form | freeze-dried powder | freeze-dried powder |
Structure
ARA-290 (cibinetide) is an 11-residue linear peptide (pGlu-EQLERALNSS) modelled on helix B of erythropoietin. PubChem CID 91810664 lists the formula C51H84N16O21 and a computed molecular weight of 1257.3 g/mol (https://pubchem.ncbi.nlm.nih.gov/compound/91810664).
Cartalax is the tripeptide Ala-Glu-Asp (AED). PubChem CID 87815447 lists the formula C12H19N3O8 and a computed molecular weight of 333.29 g/mol (https://pubchem.ncbi.nlm.nih.gov/compound/87815447).
Both are peptides, so the meaningful structural differences are sequence, length and modifications rather than chemical category. Differences in residue count, terminal capping (acetylation or amidation), non-natural amino acids and lipid side chains all change molecular weight, solubility and how a compound behaves in an assay. Matching like with like at the structural level is the first step before any comparison of experimental results.
Molecular weight in context
On PubChem's computed figures, ARA-290 (cibinetide) is a mid-sized peptide (1,000 to 3,000 g/mol) and Cartalax is a small molecule-sized compound (under 1,000 g/mol). The difference is 924.0 g/mol.
Molecular weight matters in practice for three reasons. First, one milligram of a lighter compound contains more molecules than one milligram of a heavier one, so equal milligram amounts are not equal molar amounts. Second, the expected mass is what identity testing checks against: mass spectrometry on a certificate of analysis should report a value consistent with the formula. Third, salt forms (for example acetate or TFA counter-ions) and metal complexes add mass that a free-base figure does not show, so a certificate may legitimately quote a slightly different value from a database entry.
Class and research context
ARA-290 (cibinetide): studied as a ligand of the innate repair receptor (EPOR/CD131 heteromer) without the haematopoietic activity of erythropoietin.
Cartalax: one of the short synthetic peptides described in the bioregulator literature of V. Khavinson.
These descriptions summarise how each compound is characterised in the published literature and in chemical databases. They are not claims about effects in people, and Sable gives no administration or medical-use information for either compound. Readers who need mechanism detail should go to the primary sources and the PubChem literature sections linked below.
How to compare them fairly
- Compare identity first: formula, sequence and expected mass, then purity.
- Compare amounts only at the same milligram size, remembering that equal milligrams are not equal moles.
- Ask for the certificate of analysis for the specific batch. At Sable, every vial is released at ≥99% purity by HPLC with identity checked against the expected mass, and certificates are available for every lot.
- Treat a search pairing as a navigation habit, not as evidence that two compounds do the same thing.
Sable listings
Vial sizes as listed on 2026-10-10. Each product page carries the current catalogue details.
ARA-290 (cibinetide) (compound guide: https://www.sablepeptides.co.uk/ara-290-uk): - ARA-290 5 mg: https://www.sablepeptides.co.uk/product/ara-290-5mg - ARA-290 16 mg: https://www.sablepeptides.co.uk/product/ara-290-16mg
Cartalax (compound guide: https://www.sablepeptides.co.uk/cartalax-uk): - Cartalax 10 mg: https://www.sablepeptides.co.uk/product/cartalax-10mg - Cartalax 20 mg: https://www.sablepeptides.co.uk/product/cartalax-20mg
Peptide vials contain freeze-dried powder only; bacteriostatic water is listed separately. Research use only. Not a medicine. Not for human or veterinary use.
Sources
- PubChem, ARA-290 (cibinetide): https://pubchem.ncbi.nlm.nih.gov/compound/91810664
- PubChem, Cartalax: https://pubchem.ncbi.nlm.nih.gov/compound/87815447
- Sable price index and methodology: https://www.sablepeptides.co.uk/pricing/methodology
- Sable quality and certificate requests: https://www.sablepeptides.co.uk/quality
Comparison questions
What is the difference between ARA-290 (cibinetide) and Cartalax?
ARA-290 (cibinetide) and Cartalax are different compounds. ARA-290 (cibinetide) is an erythropoietin-derived linear peptide; Cartalax is a short regulatory tripeptide (Khavinson series). By PubChem's computed values, ARA-290 (cibinetide) (1257.3 g/mol) is about 3.8 times the mass of Cartalax (333.29 g/mol). Sable lists both as freeze-dried research material. Research use only: neither is sold as a medicine, and neither is for use in people or animals.
What are the molecular weights of ARA-290 (cibinetide) and Cartalax?
ARA-290 (cibinetide): 1257.3 g/mol (PubChem CID 91810664); Cartalax: 333.29 g/mol (PubChem CID 87815447).
Are these sold for use in people?
No. Both are laboratory research material only: not medicines, and not for use in people or animals. No administration or medical-use information is provided.